NovaBridge Biosciences Announced Sunday, Updated Phase 1b Givastomig Combination Data Showing 79% ORR At 8 Mg/Kg In First-Line HER2-Negative Metastatic Gastroesophageal Adenocarcinoma At ESMO

Loading news article.

NovaBridge Biosciences Announced Sunday, Updated Phase 1b Givastomig Combination Data Showing 79% ORR At 8 Mg/Kg In First-Line HER2-Negative Metastatic Gastroesophageal Adenocarcinoma At ESMO | WAPE

NovaBridge Biosciences Announced Sunday, Updated Phase 1b Givastomig Combination Data Showing 79% ORR At 8 Mg/Kg In First-Line HER2-Negative Metastatic Gastroesophageal Adenocarcinoma At ESMO

Article summary

Related companies

Comments —